Hong Kong and the Next Generation of Cell & Gene Therapies
With Hong Kong now host to a growing volume of public and private entities specializing in cell and gene therapy development, some market insiders spy great opportunities for the city,…
Company information:
Hybribio is a leading provider for in vitro diagnostic assays in Greater China with fully integrated operation chain from R&D, manufacturing, sales & marketing to after-sales technical support service. As of year 2016, over 16 million tests of our HPV Genotyping test has been performed in China. Furthermore, we are the sole company collaborating with the Ministry of Health in Chinese Government to establish the first HPV database system in China. Based on technological platforms such as our proprietary flow-through hybridization technology, real-time PCR technology, and high throughput sequencing, our two major R&D lines – infectious pathogens detection and genetic disease detection – include human papillomavirus (HPV), thalassemia, G6PD, hearing loss susceptibility, phenylketonuria (PKU), and early cancer detection etc. Our products have been widely used in the fields of clinical detection, large scale screening, and prenatal and neonatal management.
Address: 27/F, Bonham Trade Centre, 50 Bonham Strand, Sheung Wan, Hong Kong
Tel.: (+852) 2851 8029
Website: http://hybribio.com/
Email: marketing@hybribio.com
With Hong Kong now host to a growing volume of public and private entities specializing in cell and gene therapy development, some market insiders spy great opportunities for the city,…
At first glance, tiny and crowded Hong Kong may not look like an obvious destination for developing next-generation gene therapies, for all its financial firepower and international complexion. Delve deeper,…
In summer 2023, Hong Kong entered the next frontier of cancer care with the launch of its first hospital-based CAR-T clinical trial. Developed entirely within city limits by a team…
Hong Kong has a burgeoning status within Greater China as an advanced therapy hub. The Special Administrative Region boasts clinical trial expertise, internationally aligned regulation, a lack of price caps,…
Hong Kong’s unique history as a former British governate and current special status under the ‘one country, two systems’ administrative framework, endow it with many underlying advantages as a ‘talent…
In March 2024, the Advanced Therapy Product Good Manufacturing Practice Centre (ATP GMP Centre) at the Chinese University of Hong Kong’s (CUHK) Institute of Biotechnology (HKIB) became the first university-led…
With global momentum building around CRISPR-based therapeutics, GenEditBio stands at the frontier of in vivo genome editing, developing next-generation delivery platforms designed for both precision and safety. In this conversation,…
Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year,…
Hong Kong has grand plans to become one of Asia’s leading clinical trial hubs. Important regulatory upgrades and increased integration with mainland China via the Greater Bay Area initiative –…
Hong Kong’s ambitious plans to transform into an “innovation and technology” hub will require careful and deliberate combinations of Hong Kong and mainland capabilities. From this understanding, the idea for…
Since we last covered Hong Kong in Summer 2023, the territory’s regulatory landscape has taken a major step towards its long-term goal of establishing a full regulatory authority. Having previously…
It has been an extremely challenging couple of years for Hong Kong’s financial sector, including for the wealth of biotech companies listed in the city, but fundamentals remain strong, and…
See our Cookie Privacy Policy Here
